XOMA Royalty Corporation (XOMA)
NASDAQ: XOMA · Real-Time Price · USD
27.45
+1.47 (5.66%)
At close: Mar 9, 2026, 4:00 PM EDT
27.47
+0.02 (0.07%)
After-hours: Mar 9, 2026, 4:24 PM EDT

Company Description

XOMA Royalty Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific.

It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates.

The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets.

It has a portfolio with various assets. The company was formerly known as XOMA Corporation and changed its name to XOMA Royalty Corporation in July 2024.

XOMA Royalty Corporation was incorporated in 1981 and is headquartered in Emeryville, California.

XOMA Royalty Corporation
XOMA Royalty logo
Country United States
Founded 1981
Industry Biotechnology
Sector Healthcare
Employees 13
CEO Owen Hughes

Contact Details

Address:
2200 Powell Street, Suite 310
EmeryVille, California 94608
United States
Phone 510 204 7200
Website xoma.com

Stock Details

Ticker Symbol XOMA
Exchange NASDAQ
Stock Type Common Stock
Fiscal Year January - December
Reporting Currency USD
CIK Code 0000791908
CUSIP Number 98419J206
ISIN Number US98419J2069
Employer ID 52-2154066
SIC Code 2834

Key Executives

Name Position
Owen P. Hughes Jr. Chief Executive Officer and Director
Bradley Sitko Chief Investment Officer
Jeffrey Trigilio Chief Financial Officer
Maricel Perea Montano Chief Legal Officer

Latest SEC Filings

Date Type Title
Mar 6, 2026 SCHEDULE 13G/A Filing
Mar 2, 2026 8-K Current Report
Feb 12, 2026 SCHEDULE 13G/A Filing
Feb 9, 2026 8-K Current Report
Feb 2, 2026 8-K/A [Amend] Current report
Jan 15, 2026 8-K Current Report
Jan 12, 2026 8-K Current Report
Dec 5, 2025 8-K Current Report
Nov 21, 2025 8-K Current Report
Nov 12, 2025 8-K Current Report